Karuna Therapeutics Inc (DELISTED) (KRTX:DL)
329.83
0.00 (0.00%)
USD |
NASDAQ |
Mar 18, 16:00
Karuna Therapeutics Research and Development Expense (Quarterly): 82.19M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 82.19M |
September 30, 2023 | 103.95M |
June 30, 2023 | 92.49M |
March 31, 2023 | 85.47M |
December 31, 2022 | 66.00M |
September 30, 2022 | 61.95M |
June 30, 2022 | 52.49M |
March 31, 2022 | 43.81M |
December 31, 2021 | 45.09M |
September 30, 2021 | 38.78M |
June 30, 2021 | 24.15M |
March 31, 2021 | 20.19M |
Date | Value |
---|---|
December 31, 2020 | 15.58M |
September 30, 2020 | 12.58M |
June 30, 2020 | 10.82M |
March 31, 2020 | 4.42M |
December 31, 2019 | 4.992M |
September 30, 2019 | 5.793M |
June 30, 2019 | 6.784M |
March 31, 2019 | 6.967M |
December 31, 2018 | 6.72M |
September 30, 2018 | 1.417M |
June 30, 2018 | 2.175M |
March 31, 2018 | 1.224M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
4.42M
Minimum
Mar 2020
103.95M
Maximum
Sep 2023
40.92M
Average
38.78M
Median
Sep 2021
Research and Development Expense (Quarterly) Benchmarks
Bristol-Myers Squibb Co | 2.695B |
RayzeBio inc (DELISTED) | 18.17M |
Icosavax Inc (DELISTED) | 16.67M |
Madrigal Pharmaceuticals Inc | 70.64M |
Theseus Pharmaceuticals Inc (DELISTED) | 11.52M |